China Resources Pharma Subsidiary KPC Posts Profit Slump but Maintains Dividend

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.

KPC Pharmaceuticals, Inc., a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported audited results for the year ended 31 December 2025 showing total assets of RMB11.77 billion, down 6.64% year on year, while net assets attributable to shareholders rose 2.07% to RMB5.36 billion, signaling a modest strengthening of its capital base despite balance-sheet contraction.

Operating performance weakened sharply, with revenue dropping 21.74% to RMB6.58 billion and net profit attributable to shareholders halving by 46% to RMB349.94 million, and core profit excluding extraordinary items plunging 74.45%, alongside a 64.21% fall in operating cash flow; nevertheless, KPC’s board has proposed a cash dividend of RMB1.80 per 10 shares, indicating a continued commitment to shareholder returns even as investors are cautioned that these figures reflect KPC alone rather than the overall group.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated healthcare conglomerate with a diversified portfolio spanning the development, manufacturing and distribution of pharmaceutical products across mainland China. Through subsidiaries such as China Resources Sanjiu Medical & Pharmaceutical, the group holds a controlling stake in KPC Pharmaceuticals, Inc., a Shanghai-listed drug maker focused on traditional Chinese and modern medicines.

Average Trading Volume: 9,607,392

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.28B

For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.